203 related articles for article (PubMed ID: 36969745)
1. Tumor Cell-Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer.
Chen H; Cresswell GM; Libring S; Ayers MG; Miao J; Zhang ZY; Solorio L; Ratliff TL; Wendt MK
Cancer Res Commun; 2022 Oct; 2(10):1104-1118. PubMed ID: 36969745
[TBL] [Abstract][Full Text] [Related]
2. SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer.
Chen H; Libring S; Ruddraraju KV; Miao J; Solorio L; Zhang ZY; Wendt MK
Oncogene; 2020 Dec; 39(49):7166-7180. PubMed ID: 33033382
[TBL] [Abstract][Full Text] [Related]
3. Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment.
Quintana E; Schulze CJ; Myers DR; Choy TJ; Mordec K; Wildes D; Shifrin NT; Belwafa A; Koltun ES; Gill AL; Singh M; Kelsey S; Goldsmith MA; Nichols R; Smith JAM
Cancer Res; 2020 Jul; 80(13):2889-2902. PubMed ID: 32350067
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade.
Akhand SS; Liu Z; Purdy SC; Abdullah A; Lin H; Cresswell GM; Ratliff TL; Wendt M
Cancer Immunol Res; 2020 Dec; 8(12):1542-1553. PubMed ID: 33093218
[TBL] [Abstract][Full Text] [Related]
5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
6. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
7. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8
Fang W; Zhou T; Shi H; Yao M; Zhang D; Qian H; Zeng Q; Wang Y; Jin F; Chai C; Chen T
J Exp Clin Cancer Res; 2021 Jan; 40(1):4. PubMed ID: 33390170
[TBL] [Abstract][Full Text] [Related]
8. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
9. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
[TBL] [Abstract][Full Text] [Related]
10. The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1.
Erlichman N; Meshel T; Baram T; Abu Raiya A; Horvitz T; Ben-Yaakov H; Ben-Baruch A
Cells; 2023 Sep; 12(19):. PubMed ID: 37830552
[TBL] [Abstract][Full Text] [Related]
11. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
12. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
13. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of TGFβ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1.
Chen TW; Hung WZ; Chiang SF; Chen WT; Ke TW; Liang JA; Huang CY; Yang PC; Huang KC; Chao KSC
Cancer Lett; 2022 Sep; 543():215795. PubMed ID: 35718267
[TBL] [Abstract][Full Text] [Related]
16. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
17. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
18. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
[TBL] [Abstract][Full Text] [Related]
19. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
20. Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function.
Petty AJ; Dai R; Lapalombella R; Baiocchi RA; Benson DM; Li Z; Huang X; Yang Y
JCI Insight; 2021 Mar; 6(6):. PubMed ID: 33749663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
